Move Over Gilead? AbbVie Could Bring Serious Competition to HCV Market WESTPORT, CT--(Marketwired - Oct 13, 2014) - Gilead's Harvoni (sofosbuvir/ledipasvir combination) is the top overall scorer, according to RxScorecard, a drug-value assessment tool from Real...

Reimbursement Intelligence Announces a Series of Major Key Strategic and Organization Changes MADISON, NJ--(Marketwired - Jan 15, 2014) - Reimbursement Intelligence (RI), an information and marketing services firm that provides expert insights and solutions about the changing healthcare...

Cancer Drug Costs Unsustainable, According to Value & Innovation Webinar WESTPORT, CT--(Marketwire - Mar 30, 2012) - The current economic model for treating cancer is badly broken, according to senior executives from healthcare insurance companies who discussed the...

Real Endpoints Launches New Reimbursement-Focused Information Service WESTPORT, CT--(Marketwire - Nov 29, 2011) - Real Endpoints LLC, a new information company focused on healthcare reimbursement, announced today the launch of its Value & Innovation LLC...